Axon Prices $1 Billion in Convertible Notes to Fuel Growth

The offering includes an option for underwriters to purchase an additional $150 million in notes to cover potential over-allotments. Axon has designated approximately $100 million of the proceeds to fund capped call transactions, which are intended to mitigate stock dilution for existing shareholders should the notes be converted. The remaining capital is earmarked for general corporate purposes, including investments in new product lines and strategic business acquisitions.

These senior, unsecured notes carry no regular interest and are set to mature on September 15, 2031. Investors may convert the debt into common stock at an initial rate of 1.5336 shares per $1,000 of principal, translating to a conversion price of roughly $652.06 per share. A syndicate of financial institutions, led by Goldman Sachs, Morgan Stanley, J.P. Morgan, RBC Capital Markets, and Citigroup, is managing the offering. The company’s decision to enter into capped call transactions is expected to influence the market price of its common stock, as counterparties establish and hedge their positions in connection with the deal.